# SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

> **NCT04898322** · PHASE2 · UNKNOWN · sponsor: **Suzhou Yabao Pharmaceutical R&D Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** SY-005
- **DRUG:** SY-005
- **DRUG:** SY-005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04898322
- **Lead sponsor:** Suzhou Yabao Pharmaceutical R&D Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-02
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898322, "SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04898322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*